Chapter 1. EMEA Point-of-Care Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. EMEA Point-of-Care Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Product Snapshot
2.3. End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. EMEA Point-of-Care Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising Burden of Chronic and Infectious Diseases
3.4.2. Shift Toward Decentralized Healthcare
3.4.3. Technological Advancements in POC Devices
3.5. Market Restraint Analysis
3.5.1. Regulatory and Quality Compliance Challenges
3.5.2. Limited Access in Low-Income Regions
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. EMEA Point-of-Care Diagnostics Market: Product Estimates & Trend Analysis
4.1. EMEA Point-of-Care Diagnostics Market: Product Movement Analysis
4.2. Glucose Testing
4.2.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.3. Hb1Ac Testing
4.3.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.4. Coagulation Testing
4.4.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.5. Fertility/Pregnancy
4.5.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6. Infectious Disease
4.6.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.2. HIV POC
4.6.2.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.3. Clostridium Difficile POC
4.6.3.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.4. HBV POC
4.6.4.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.5. Pneumonia or Streptococcus Associated Infections
4.6.5.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.6. Respiratory Syncytial Virus (RSV) POC
4.6.6.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.7. HPV POC
4.6.7.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.8. Influenza/Flu POC
4.6.8.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.9. HCV POC
4.6.9.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.10. MRSA POC
4.6.10.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.11. TB and Drug-resistant TB POC
4.6.11.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.12. HSV POC
4.6.12.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.13. COVID-19
4.6.13.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6.14. Urinalysis/Nephrology
4.6.14.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.7. Cardiac Markers
4.7.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.8. Thyroid Stimulating Hormone
4.8.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.9. Hematology
4.9.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.10. Primary Care Systems
4.10.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.11. Decentralized Clinical Chemistry
4.11.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.12. Feces
4.12.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.13. Lipid Testing
4.13.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.14. Cancer Marker
4.14.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.15. Blood Gas/Electrolytes
4.15.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.16. Ambulatory Chemistry
4.16.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.17. Drug of Abuse (DOA) Testing
4.17.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.18. Autoimmune Diseases
4.18.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.19. Urinalysis/Nephrology
4.19.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. EMEA Point-of-Care Diagnostics Market: End Use Estimates & Trend Analysis
5.1. EMEA Point-of-Care Diagnostics Market: End Use Movement Analysis
5.2. Clinics
5.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.2.2. Pharmacy & Retail Clinics
5.2.2.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
5.2.3. Physician Office
5.2.3.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
5.2.4. Urgent Care Clinics
5.2.4.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
5.3. Hospitals
5.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.4. Home
5.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Assisted Living Healthcare Facilities
5.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.6. Laboratory
5.6.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. EMEA Point-of-Care Diagnostics Market: Regional Business Analysis
6.1. Regional Market Snapshot
6.2. Europe
6.2.1. Europe EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.2. UK
6.2.2.1. UK EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.2.2. Key Country Dynamics
6.2.2.3. Regulatory Framework
6.2.2.4. Reimbursement Scenario
6.2.2.5. Competitive Scenario
6.2.3. Germany
6.2.3.1. Germany EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.3.2. Key Country Dynamics
6.2.3.3. Regulatory Framework
6.2.3.4. Reimbursement Scenario
6.2.3.5. Competitive Scenario
6.2.4. Spain
6.2.4.1. Spain EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.4.2. Key Country Dynamics
6.2.4.3. Regulatory Framework
6.2.4.4. Reimbursement Scenario
6.2.4.5. Competitive Scenario
6.2.5. France
6.2.5.1. France EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.5.2. Key Country Dynamics
6.2.5.3. Regulatory Framework
6.2.5.4. Reimbursement Scenario
6.2.5.5. Competitive Scenario
6.2.6. Italy
6.2.6.1. Italy EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.6.2. Key Country Dynamics
6.2.6.3. Regulatory Framework
6.2.6.4. Reimbursement Scenario
6.2.6.5. Competitive Scenario
6.2.7. Denmark
6.2.7.1. Denmark EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.7.2. Key Country Dynamics
6.2.7.3. Regulatory Framework
6.2.7.4. Reimbursement Scenario
6.2.7.5. Competitive Scenario
6.2.8. Sweden
6.2.8.1. Sweden EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.8.2. Key Country Dynamics
6.2.8.3. Regulatory Framework
6.2.8.4. Reimbursement Scenario
6.2.8.5. Competitive Scenario
6.2.9. Norway
6.2.9.1. Norway EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.2.9.2. Key Country Dynamics
6.2.9.3. Regulatory Framework
6.2.9.4. Reimbursement Scenario
6.2.9.5. Competitive Scenario
6.3. MEA
6.3.1. MEA EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.3.2. South Africa
6.3.2.1. South Africa EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.3.2.2. Key Country Dynamics
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Scenario
6.3.2.5. Competitive Scenario
6.3.3. Saudi Arabia
6.3.3.1. Saudi Arabia EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.3.3.2. Key Country Dynamics
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Scenario
6.3.3.5. Competitive Scenario
6.3.4. UAE
6.3.4.1. UAE EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.3.4.2. Key Country Dynamics
6.3.4.3. Regulatory Framework
6.3.4.4. Reimbursement Scenario
6.3.4.5. Competitive Scenario
6.3.5. Kuwait
6.3.5.1. Kuwait EMEA Point-of-Care Diagnostics Market, 2021-2033 (USD Million)
6.3.5.2. Key Country Dynamics
6.3.5.3. Regulatory Framework
6.3.5.4. Reimbursement Scenario
6.3.5.5. Competitive Scenario
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.2.1. New Biomarker Launch
7.2.2. Partnerships
7.2.3. Acquisition
7.2.4. Collaboration
7.2.5. Funding
7.3. Key Company Market Share Analysis, 2024
7.4. Company Heat Map Analysis
7.5. Company Profiles
7.5.1. F. Hoffmann-La Roche Ltd
7.5.1.1. Company Overview
7.5.1.2. Financial Performance
7.5.1.3. Biomarker Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. QIAGEN
7.5.2.2. Financial Performance
7.5.2.3. Biomarker Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Danaher Corporation
7.5.3.1. Company Overview
7.5.3.2. Financial Performance
7.5.3.3. Biomarker Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. BD
7.5.4.1. Company Overview
7.5.4.2. Financial Performance
7.5.4.3. Biomarker Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. bioMérieux
7.5.5.1. Company Overview
7.5.5.2. Financial Performance
7.5.5.3. Biomarker Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Abbott
7.5.6.1. Company Overview
7.5.6.2. Financial Performance
7.5.6.3. Biomarker Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Siemens Healthcare Private Limited
7.5.7.1. Company Overview
7.5.7.2. Financial Performance
7.5.7.3. Biomarker Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Werfen
7.5.8.1. Company Overview
7.5.8.2. Financial Performance
7.5.8.3. Biomarker Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Nova Biomedical
7.5.9.1. Company Overview
7.5.9.2. Financial Performance
7.5.9.3. Biomarker Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Trividia Health, Inc.
7.5.10.1. Company Overview
7.5.10.2. Financial Performance
7.5.10.3. Biomarker Benchmarking
7.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 EMEA Point-of-Care Diagnostics Market, by Region, 2021-2033 (USD Million)
Table 4 EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 5 EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 6 Europe EMEA Point-of-Care Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 7 Europe EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 8 Europe EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 9 UK EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 10 UK EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 11 Germany EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 12 Germany EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 13 France EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 14 France EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 15 Italy EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 16 Italy EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 17 Spain EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 18 Spain EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 19 Sweden EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 20 Sweden EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 21 Norway EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 22 Norway EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 23 Denmark EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 24 Denmark EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 25 MEA EMEA Point-of-Care Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 26 MEA EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 27 MEA EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 28 South Africa EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 29 South Africa EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 30 Saudi Arabia EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 31 Saudi Arabia EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 32 UAE EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD Million)
Table 33 UAE EMEA Point-of-Care Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 34 Kuwait EMEA Point-of-Care Diagnostics Market, by Product, 2021-2033 (USD)
Table 35 Kuwait EMEA Point-of-Care Diagnostics Market, by End Use, 32021 - 2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Market summary
Figure 4 Market segmentation & scope
Figure 5 Market size and growth prospects
Figure 6 EMEA Point-of-Care Diagnostics market- Key market driver analysis
Figure 7 EMEA Point-of-Care Diagnostics market - Key market restraint analysis
Figure 8 Penetration & growth prospect mapping
Figure 9 EMEA Point-of-Care Diagnostics market - Porter’s analysis
Figure 10 EMEA Point-of-Care Diagnostics market - PESTEL analysis
Figure 11 EMEA Point-of-Care Diagnostics market Product outlook key takeaways
Figure 12 EMEA Point-of-Care Diagnostics market: Product movement analysis
Figure 13 Glucose Testing market estimates, 2021-2033 (USD Million)
Figure 14 Circulating Tumor Cells (CTCs) market estimates, 2021-2033 (USD Million)
Figure 15 Hb1Ac Testing market estimates, 2021-2033 (USD Million)
Figure 16 Coagulation Testing market estimates, 2021-2033 (USD Million)
Figure 17 Fertility/Pregnancy market estimates, 2021-2033 (USD Million)
Figure 18 Infectious Disease market estimates, 2021-2033 (USD Million)
Figure 19 HIV POC market estimates, 2021-2033 (USD Million)
Figure 20 Clostridium Difficile POC market estimates, 2021-2033 (USD Million)
Figure 21 HBV POC market estimates, 2021-2033 (USD Million)
Figure 22 Pneumonia or Streptococcus Associated Infections market estimates, 2021-2033 (USD Million)
Figure 23 Respiratory Syncytial Virus (RSV) POC market estimates, 2021-2033 (USD Million)
Figure 24 HPV POC market estimates, 2021-2033 (USD Million)
Figure 25 Influenza/Flu POC market estimates, 2021-2033 (USD Million)
Figure 26 HCV POC market estimates, 2021-2033 (USD Million)
Figure 27 MRSA POC market estimates, 2021-2033 (USD Million)
Figure 28 TB and Drug-resistant TB POC market estimates, 2021-2033 (USD Million)
Figure 29 HSV POC market estimates, 2021-2033 (USD Million)
Figure 30 COVID-19 market estimates, 2021-2033 (USD Million)
Figure 31 Urinalysis/Nephrology market estimates, 2021-2033 (USD Million)
Figure 32 Cardiac Markers market estimates, 2021-2033 (USD Million)
Figure 33 Thyroid Stimulating Hormone market estimates, 2021-2033 (USD Million)
Figure 34 Hematology market estimates, 2021-2033 (USD Million)
Figure 35 Primary Care Systems market estimates, 2021-2033 (USD Million)
Figure 36 Decentralized Clinical Chemistry market estimates, 2021-2033 (USD Million)
Figure 37 Feces market estimates, 2021-2033 (USD Million)
Figure 38 Lipid Testing market estimates, 2021-2033 (USD Million)
Figure 39 Cancer Marker market estimates, 2021-2033 (USD Million)
Figure 40 Blood Gas/Electrolytes market estimates, 2021-2033 (USD Million)
Figure 41 Ambulatory Chemistry market estimates, 2021-2033 (USD Million)
Figure 42 Drug of Abuse (DOA) Testing market estimates, 2021-2033 (USD Million)
Figure 43 Autoimmune Diseases market estimates, 2021-2033 (USD Million)
Figure 44 Urinalysis/Nephrology market estimates, 2021-2033 (USD Million)
Figure 45 EMEA Point-of-Care Diagnostics market End Use outlook key takeaways
Figure 46 EMEA Point-of-Care Diagnostics market: End Use movement analysis
Figure 47 Clinics market estimates, 2021-2033 (USD Million)
Figure 48 Pharmacy & Retail Clinics market estimates, 2021-2033 (USD Million)
Figure 49 Physician Office market estimates, 2021-2033 (USD Million)
Figure 50 Urgent Care Clinics market estimates, 2021-2033 (USD Million)
Figure 51 Hospitals market estimates, 2021-2033 (USD Million)
Figure 52 Home market estimates, 2021-2033 (USD Million)
Figure 53 Assisted Living Healthcare Facilities market estimates, 2021-2033 (USD Million)
Figure 54 Laboratory market estimates, 2021-2033 (USD Million)
Figure 55 Regional marketplace: Key takeaways
Figure 56 EMEA Point-of-Care Diagnostics market: Regional movement analysis
Figure 57 Europe EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 58 UK EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 59 Germany EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 60 France EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 61 Spain EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 62 Italy EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 63 Denmark EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 64 Sweden EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 65 Norway EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 66 MEA EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 67 South Africa EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 68 Saudi Arabia EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 69 UAE EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 70 Kuwait EMEA Point-of-Care Diagnostics market, 2021-2033 (USD Million)
Figure 71 Strategy framework
